ArticleDiscover nano2026
Advanced fluorescence biosensor utilizing nitrogen/oxygen-doped carbon quantum dots in a modified carboxy cellulose matrix for quantitative detection of SARS-CoV-2 spike protein.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The persistent need for fast and sensitive point-of-care (POC) diagnostics for SARS-CoV-2 requires alternatives to time-consuming RT-PCR. To address this challenge, we designed and fabricated a novel fluorescence biosensor based on nitrogen/oxygen-doped carbon quantum dots embedded in an epichlorohydrin-modified carboxymethyl cellulose thin film. This robust and easily synthesized platform enabled the immobilization of spike protein-specific monoclonal antibodies, facilitating detection via fluorescence quenching and recovery at Ex/Em 320 nm/440 nm. The biosensor was characterized using Fourier-transform infrared spectroscopy, transmission electron microscopy, X-ray photoelectron spectroscopy, and fluorescence spectroscopy, confirming successful doping, nanoscale morphology, and stable optical properties. The biosensor achieved a remarkably low limit of detection of 0.0323 pg/mL across a wide dynamic range of 3.1-700 pg/mL. When validated with clinical nasal swab samples, it demonstrated high analytical performance, with a sensitivity of 95.13% and specificity of 93.1%, along with excellent reproducibility and room-temperature stability. This rapid, cost-effective fluorescence biosensor represents a significant advancement for POC SARS-CoV-2 testing, offering a practical solution for clinical and decentralized diagnosis, especially in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.